Determination of the composition of pharmaceutical substances used in drugs with antiarrhythmic activity-Reference-Cited by-同舟云学术

Determination of the composition of pharmaceutical substances used in drugs with antiarrhythmic activity

Published:2024-01-22 Issue:4 Volume: Page:95-109
ISSN:2686-8830
Container-title:Pharmacokinetics and Pharmacodynamics
language:
Short-container-title:Fk&Fd

Author:

Rogov A. V.¹^ORCID,Mokrov G. V.²^ORCID

Affiliation:

1. “Pharmcenter VILAR” JSC

2. Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies

Abstract

Cardiac arrhythmias are the most common pathologies of the cardiovascular system. Allapinin® and Allaforte® from “Pharmcenter VILAR” are effective IC-class antiarrhythmic agents. The main component of these drugs is a pharmaceutical substance with INN: lappaconitine hydrobromide, which in addition to lappaconitine hydrobromide itself, contains impurities of other diterpene alkaloids. This work is devoted to a detailed analysis of the alkaloid composition of a new pharmaceutical substance isolated from roots and rhizomes, as well as from the aerial part of plants of the genus Aconite (monkshood, wolfsbane) of the Ranunculaceae family (buttercups) using chromato-mass spectrometry and NMR spectroscopy. In addition, an assessment was made of the quantitative ratios of alkaloids in several samples of pharmaceutical substances isolated from different batches of medicinal plant raw materials.

Publisher

Publishing House OKI

Subject

Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science

Reference8 articles.

1. World Health Organization: Cardiovascular diseases (CVDs). Published 2021. Accessed October 12, 2021. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

2. Hendren NS, Drazner MH, Bozkurt B, Cooper LT Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020 Jun 9;141(23):1903–1914. DOI: 10.1161/CIRCULATIONAHA.120.047349.

3. Zhan Y, Yue H, Liang W, Wu Z. Effects of COVID-19 on Arrhythmia. J Cardiovasc Dev Dis. 2022 Sep 2;9(9):292. DOI: 10.3390/jcdd9090292.

4. Patel MH, Sampath S, Kapoor A, et al. Advances in Cardiac Pacing: Arrhythmia Prediction, Prevention and Control Strategies. Front Physiol. 2021 Dec 2;12:783241. DOI: 10.3389/fphys.2021.783241.

5. Sokolov SF, Belyaeva MM, Bakalov SA, Golitsyn SP. Lappakonitina gidrobromid i ego prolongirovannaya forma pri zheludochkovoi ekstrasistolii u bol'nykh bez organicheskoi patologii serdtsa: effektivnost' i bezopasnost'. Kardiologiya: Novosti Mneniya Obuchenie. 2018;6(2):29–37. DOI:10.24411/2309-1908-2018-12004. Sokolov SF, Belyaeva MM, Bakalov SA, Golitsyn SP. Lappaconitine hydrobromide and its sustained-release form in case of ventricular premature beats in patients without organic heart diseases: efficiency and safety. Cardiology: News, Opinions, Training. 2018;6(2):29–37. (In Russ.). DOI: 10.24411/2309-1908-2018-12004.